|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dyslipidemia and apolipoprotein E4 (APOE ϵ4) allele are risk factors for age-related cognitive decline, but how these risks are modified by human immunodeficiency virus (HIV) infection is unclear.
|
27448678 |
2016 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Dyslipidemia in LPG generally resembles type III hyperlipoproteinemia with elevated serum apolipoprotein E level.
|
30685233 |
2020 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E polymorphism in indigenous Australians: allelic frequencies and relationship with dyslipidaemia.
|
10078180 |
1999 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ApoE4 allele is associated with obesity independent of dyslipidemia in women but not men with a family history of diabetes.
|
11553047 |
2001 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Apolipoprotein E (apo E) deficiency (or its abnormalities in humans) is associated with a series of pathological conditions including dyslipidemia, atherosclerosis, Alzheimer's disease, and shorter life span.
|
11726538 |
2001 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Apolipoprotein E (apo E), a genetic determinant of plasma lipid levels and coronary heart disease (CHD) needs to be investigated in Asian Indians since they have a propensity to develop dyslipidemia and accelerated atherosclerosis.
|
12030385 |
2002 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E polymorphism is an important genetic marker for dyslipidemia.
|
16142566 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
APOE genotypes and dyslipidemias in a sample of the Portuguese population.
|
16176168 |
2005 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E gene polymorphisms are strong predictors of inflammation and dyslipidemia in rheumatoid arthritis.
|
22174202 |
2012 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
APOE genotypes are associated with lipid levels in patients with RA, and may contribute to dyslipidemia in some patients.
|
23613766 |
2013 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ApoE4 which differs from apoE3 by the single amino acid substitution Cys112Arg is also associated with dyslipidemia although binding of this isoform to the LDLR is unaffected.
|
25328986 |
2014 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
APOE and LDLR Gene Polymorphisms and Dyslipidemia Tracking. Rio de Janeiro Study.
|
26131702 |
2015 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
APOE genotype associates with food consumption and body composition to predict dyslipidaemia in Brazilian adults with normal-weight obesity syndrome.
|
28720344 |
2018 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E alleles are important genetic markers for dyslipidemia and CHD.
|
7966894 |
1994 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A similar phenotype of combined dyslipidemia was induced in apoE(-/-) or apoE(-/-) x LDLr(-/-) mice after infection with a low dose (4 x 10(8) pfu) of an adenovirus expressing the apoE4[R142V/R145V] mutant previously shown to be defective in receptor binding.
|
16339113 |
2006 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells.
|
23570453 |
2013 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
CTD_human |
Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice.
|
25037058 |
2014 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
After taking into account confounding factors and correcting for multiple comparisons only APOE rs429358 and rs7412 variants remained significantly associated with risk of dyslipidemia.
|
26043189 |
2015 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
APOB, APOC3, and APOE and apolipoprotein-defined lipoprotein subclasses (ADLSs; based on qualitative apolipoprotein complement) have been associated with dyslipidemia and CVD.
|
31203233 |
2019 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Associations of apolipoprotein E and low-density lipoprotein receptor-related protein 5 polymorphisms with dyslipidemia and generalized aggressive periodontitis in a Chinese population.
|
25329009 |
2015 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia.
|
17985658 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Further screening for common apoE gene variants in individuals at risk for dyslipidemia may reveal abnormal heteroduplex patterns and uncover further mutations in this important lipid-regulating gene.
|
15514092 |
2005 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Green tea polyphenol treatment attenuates atherosclerosis in high-fat diet-fed apolipoprotein E-knockout mice via alleviating dyslipidemia and up-regulating autophagy.
|
28777810 |
2017 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, the LDL-receptor binding defects for these apoE variants do not correlate well with the severity of dyslipidemia, indicating that these variants may carry additional properties that contribute to their pathogenic potential.
|
22069485 |
2011 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins.
|
7706948 |
1995 |